The recently identified tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway suggests that NLRP3 inflammasome inhibition could be a therapeutic target in combination with PD-1/PD-L1 immunotherapy [15,16]. This evidence concerns the gene NLRP3 and neoplasm.